Last updated on February 2019

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: PSORIATIC ARTHRITIS
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Diagnosis of PsA classified by CASPAR; Rheumatoid factor and anti-CCP antibodies negative; diagnosis of active plaque psoriasis, with at least one psoriatic plaque of 2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis; inadequate control of symptoms with NSAIDs; inadequate control of symptoms with a conventional DMARD.

Exclusion Criteria:

  • Pregnant or nursing women, evidence of ongoing infectious or malignant process; previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis; subjects taking high potency opioid analgesics; ongoing use of prohibited psoriasis treatments / medications; previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents.

Other protocol-defined inclusion/exclusion criteria may apply

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.